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Important Safety Information -- Revised Directions for Using Rabies 
Immune Globulin (Human), HyperRAB ™ S/D in Fixed Needle 2 mL Pre­
filled Syringe
The Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA) have been 
notified by Talecris Biotherapeutics, Inc. that its Rabies Immune Globulin (Human), HyperRAB™ S/D in fixed 
needle 2 mL pre-filled syringe does not address all dosing situations. Specifically, the fixed needle (22 gauge,
1.25 inch) and the absence of graduations on the 2 mL pre-filled syringe do not permit administration of the 
recommended dose of Rabies Immune Globulin (Human), HyperRAB™ S/D in one or more of the following 
situations:
• A dose < 2 mL is required (e.g. for pediatric use);
• A dose < 2 mL must be injected over multiple sites; or
• An alternate needle (different length or gauge) is required based on the patient (adult or child), wound or site
of injection.
Three lots of HyperRAB™S/D have been manufactured with the 2 mL pre-filled syringe configuration (see Table 
below):
Lot Number Expiration Date Size/Container NDC Number
26N87R1 Jan-26-2009 2 mL pre-filled syringe 13533-618-03
26N88K1 Jan-26-2009 2 mL pre-filled syringe 13533-618-03
26N9HP1 Feb-18-2010 2 mL pre-filled syringe 13533-618-03
Healthcare providers may continue to administer HyperRAB S/D supplied in the 2 mL pre-filled syringe by 
following the "Revised Directions for Use" that are packaged with these lots. The full "Revised Directions for Use" 
of these lots is available on-line: http://www.talecris.com/us/documents/FINAL_FDA_Approved_Revised_
Directions_for_Syringe_Use 21-FEB-08.pdf . Talecris has discontinued manufacturing the HyperRAB™S/D
fixed needle, 2 mL pre-filled syringe.
For additional information regarding this product, please contact Talecris on-line at www.talecris.com, or call 919­
412-1030, or toll free at 1-800-520-2807.
Human rabies PEP (post-exposure prophylaxis) is recommended when potentially infectious material (e.g. saliva) 
from a rabid animal is introduced via a bite, or comes into direct contact with broken skin or mucous membranes. 
More detailed information regarding evaluation for and administration of PEP is available at 
http://www.cdc.gov/mmwr/preview/mmwrhtml/00056176.htm.
For more information about rabies and its prevention, contact your state or local public health official or CDC at 1-
800-CDC-INFO or visit www.cdc.gov/rabies.
The Centers fo r Disease Control and Prevention (CDC) protects people's health and safety by preventing and 
controlling diseases and in juries; enhances health decisions by providing credible information on critical health 
issues; and promotes healthy living through strong partnerships w ith local, national and international
organizations.
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